–SAT-3247 treatment improved muscle repair and
regeneration in canine model of DMD
– SAT-3247 treatment also improved muscle force
in this canine model of DMD
– Satellos remains on track to initiate a Phase
1 clinical trial in Q3 2024
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:
MSCL, OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, today announced preliminary results from a
single case study of SAT-3247 treatment in a canine model of
Duchenne muscular dystrophy (DMD or Duchenne). This model
represents a severe dystrophy that closely reflects disease
progression observed in people with DMD. SAT-3247 is in development
as a novel regenerative medicine approach to treating DMD. These
data were presented at the Parent Project Muscular Dystrophy (PPMD)
30th Annual Conference this past weekend.
"We are encouraged by these initial data showing treatment with
SAT-3247 improved regeneration and muscle force in a canine model
of Duchenne," said Frank Gleeson, Co-founder and CEO of Satellos
Bioscience. "As Satellos' first results in a large animal study, we
are pleased that these findings continue to validate the
improvement in muscle repair and regeneration that we have
consistently seen in the mdx mouse model. This pilot study offers
further support that SAT-3247 treatment may be capable of restoring
muscle repair and regeneration that is impaired in people living
with Duchenne."
After treatment with SAT-3247 the animals showed an increase in
Regenerative Index (RI), a measure of the number of newly
regenerated muscle fibers versus the number of damaged and dying
muscle fibers.
“Increases in the Regenerative Index suggest that muscle repair
and regeneration is occurring,” commented Phil Lambert, Ph.D.,
Chief Scientific Officer of Satellos Bioscience. “While
preliminary, these results further build and support our
understanding of the unique mechanism of action of SAT-3247. We
continue to work diligently to advance this novel small molecule
drug candidate into a first-in-human clinical trial this
quarter.”
The highlighted results released at the PPMD conference and
available on the Company’s website here are from one of two
dystrophic animals in a pilot study in which each animal was
treated for four months with a daily oral dose of SAT-3247. A
summary of the results for the single case study animal reported is
as follows:
- After four months of SAT-3247 treatment, skeletal muscle
displayed an approximate four hundred and fifty percent (450%)
increase in Regenerative Index; and
- After two months of SAT-3247 treatment, skeletal muscle
displayed up to a one hundred percent (100%) increase in muscle
force.
About SAT-3247
SAT-3247 is designed as a once-daily, oral small molecule drug
that targets the root cause of muscle loss in degenerative
diseases, initially in Duchenne. SAT-3247 presents a novel
mechanism of action to restore impaired muscle regeneration caused
by the absence of functional dystrophin.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is an inherited disease caused by
mutations in the dystrophin gene that no longer allow the
dystrophin protein to function properly. Consequently, as
discovered by Satellos, muscle repair and regeneration are
impaired. Satellos designed SAT-3247 to restore the process of
muscle repair and regeneration by regulating a
dystrophin-independent pathway with the goal of increasing muscle
function. SAT-3247 is intended to work as a standalone therapeutic
without regard to a patient’s genetic mutation or ambulatory
status. Our approach has the potential to complement approaches
designed to restore dystrophin production.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to
developing life-improving medicines to treat degenerative muscle
diseases. Satellos has incorporated breakthrough research in muscle
stem cell polarity into a proprietary discovery platform, called
MyoReGenX™, to identify degenerative muscle diseases where deficits
in this process affect muscle regeneration and are amenable to
therapeutic intervention. With this platform, Satellos is building
a pipeline of novel therapeutics to correct muscle stem cell
polarity and promote the body’s innate muscle repair and
regeneration process. The Company’s lead program is an oral, small
molecule drug candidate in development as a potential
disease-modifying treatment for Duchenne muscular dystrophy.
Satellos is headquartered in Toronto, Ontario. For more
information, visit www.satellos.com.
Notice on Forward-Looking Statements
This press release includes forward-looking information or
forward-looking statements within the meaning of applicable
securities laws regarding Satellos and its business, which may
include, but are not limited to, statements regarding the
anticipated benefits to patients from a small molecule treatment
for Duchenne; the advancement of our lead drug candidate into
clinical trials; our belief that assessing regenerative status in
skeletal muscle could potentially provide a meaningful way to
predict functional outcomes in future clinical trial,, the
pharmacodynamic properties and mechanism-of-action of our lead drug
candidate; the potential of our approach in other degenerative
muscle diseases or in muscle injury or trauma; the general benefits
of modulating stem cell polarity by administering small molecule
drugs; its/their prospective impact on Duchenne patients, patients
with other degenerative muscle disease or muscle injury or trauma,
and on muscle regeneration generally; the utility of regenerating
muscle by modulating polarity; adoption of Satellos’ approach by
the medical community; and Satellos’ technologies and drug
development plans. All statements that are, or information which
is, not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, occurrences or developments, are
“forward-looking information or statements.” Often but not always,
forward-looking information or statements can be identified by the
use of words such as “shall”, “intends”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”,
“prospective” , “assert” or any variations (including negative or
plural variations) of such words and phrases, or state that certain
actions, events or results “may”, “might”, “can”, “could”, “would”
or “will” be taken, occur, lead to, result in, or, be achieved.
Such statements are based on the current expectations and views of
future events of the management of the Company. They are based on
assumptions and subject to risks and uncertainties. Although
management believes that the assumptions underlying these
statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this release,
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including, without limitation, risks relating to the pharmaceutical
and bioscience industry (including the risks associated with
preclinical and clinical trials and regulatory approvals), and the
research and development of therapeutics, the results of
preclinical and clinical trials, general market conditions and
equity markets, economic factors and management’s ability to manage
and to operate the business of the Company generally, including
inflation and the costs of operating a biopharma business, and
those risks listed in the “Risk Factors” section of Satellos’
Annual Information Form dated March 26, 2024 (which is located on
Satellos’ profile at www.sedarplus.ca). Although Satellos has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward- looking statement can be guaranteed.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Satellos does not undertake any obligation to publicly update or
revise any forward-looking statement, whether resulting from new
information, future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702994295/en/
Investors: Liz Williams, ir@satellos.com Business Development:
Ryan Mitchell, Ph.D., bd@satellos.com Media: Jessica Yingling,
Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSX:MSCL)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Satellos Bioscience (TSX:MSCL)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
